Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS) - BioSpace

Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)  BioSpace

Published: Jun 24, 2019. STAINES-UPON-THAMES, United Kingdom, June 24, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty ...



Comments

Popular posts from this blog

Tennis star Camila Giorgi asked about COVID-19 vaccination certificate: Family doc - Toronto Sun

Internal vs. Family Medicine: Who's Who in Primary Care - Avera Health

Ebstein's Anomaly: Symptoms, Causes, and Treatments - Verywell Health